Published by Alexander Bueso on 3rd February 2022
(Sharecast News) - Merck blasted past analysts' estimates for its fourth quarter earnings, helped by sales of its new Covid-19 treatment Molnupiravir.
URL: http://www.digitallook.com/dl/news/story/32439075/...